Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06613997Phase 3Not Yet Recruiting

21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia

Role: lead

NCT06252961Phase 2Recruiting

A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects

Role: lead

NCT04049630Phase 2Completed

Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients

Role: lead

All 3 trials loaded